111, Inc. Sponsored ADR (NASDAQ:YI – Get Free Report) Director Yang Luke Chen sold 44,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $0.23, for a total value of $10,120.00. Following the completion of the transaction, the director directly owned 495,462 shares in the company, valued at $113,956.26. The trade was a 8.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Yang Luke Chen also recently made the following trade(s):
- On Friday, June 12th, Yang Luke Chen sold 49,920 shares of 111 stock. The shares were sold at an average price of $0.23, for a total value of $11,481.60.
- On Wednesday, May 27th, Yang Luke Chen sold 3,400 shares of 111 stock. The shares were sold at an average price of $0.25, for a total value of $850.00.
- On Tuesday, May 26th, Yang Luke Chen sold 1,440 shares of 111 stock. The shares were sold at an average price of $0.27, for a total value of $388.80.
111 Stock Down 6.5%
YI stock opened at $4.57 on Tuesday. 111, Inc. Sponsored ADR has a twelve month low of $2.48 and a twelve month high of $11.17. The stock has a market cap of $40.17 million, a P/E ratio of -3.26 and a beta of 0.60. The business’s 50-day moving average price is $5.88 and its 200-day moving average price is $5.66.
Analyst Upgrades and Downgrades
111 Company Profile
111, Inc (NASDAQ: YI) is a leading online pharmacy e-commerce platform in China, operating under the brand 111.com. The company provides consumers with a comprehensive selection of pharmaceutical and healthcare products through its proprietary digital channels, including a website and mobile applications. By integrating online ordering, prescription management, and direct-to-consumer delivery, 111, Inc aims to streamline the purchase of medicines and health-related goods for customers nationwide.
111, Inc’s product portfolio encompasses prescription and over-the-counter drugs, nutritional supplements, vitamins, maternal and child care items, personal care products, and beauty goods.
Further Reading
- Five stocks we like better than 111
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
